Mometasone

Generic Name: Mometasone

Brand Names: Asmanex, Dulera, Elocom, Elocon, Nasonex, Ryaltris, Sinuva, Zenhale

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₀Cl_₂O_₆

CAS Number: 83919-23-7

Unique Ingredient Identifier: 04201GDN4R

Background: Mometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions. It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and higher than many other corticosteroids as well. Mometasone furoate is formulated as a dry powder inhaler, nasal spray, and ointment for its different indications.

Indication: Inhaled mometasone furoate is indicated for prophylaxis of asthma in patients ≥4 years. Applied topically as an ointment, mometasone furoate is indicated for symptomatic treatment of dermatitis and pruritis in patients ≥2 years.

Mometasone furoate nasal spray is available both over-the-counter (OTC) and by prescription. The OTC nasal spray formulation of mometasone furoate is indicated for the treatment of upper respiratory allergic symptoms (e.g. rhinorrhea, sneezing) in patients ≥2 years of age. The prescription formulation is indicated for the treatment of chronic rhinosinusitis with nasal polyps in patients ≥18 year old and for the and prophylaxis of seasonal allergic rhinitis in patients ≥12 years old. It is also approved in combination with olopatadine for the symptomatic treatment of seasonal allergic rhinitis in patients ≥12 years.

Associated Conditions: Asthma, Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Dermatitis, Dermatitis, Eczematous caused by superficial Fungal skin infection, Moderate to Severe Plaque Psoriasis, Pruritus, Psoriasis, Psoriasis, Moderate to Severe, Seasonal Allergic Rhinitis, Seasonal Allergies, Skin Diseases, Eczematous, Skin Infections, Moderate, severe Seasonal Allergic Rhinitis, Ocular effects

Associated Therapies: -

Clinical Trials

Clinical Trial to Assess Efficacy, Safety, Treatment Adherence and Quality of Life Impact of Mometasone Furoate in Asthmatic Patients (Study P04879)(TERMINATED)

Phase 4

Terminated

Conditions: Asthma

Interventions: Drug: Mometasone Furoate

First Posted Date: 2008-05-30

Last Posted Date: 2024-05-24

Lead Sponsor: Organon and Co

Target Recruit Count: 385

Registration Number: NCT00687531

Study of CRx-191 to Assess Activity in Plaque Psoriasis

Phase 2

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Vehicle (placebo)
Drug: mometasone furoate
Drug: nortriptyline HCl

First Posted Date: 2007-11-14

Last Posted Date: 2008-09-25

Lead Sponsor: Zalicus

Target Recruit Count: 20

Registration Number: NCT00557739

Locations: 🇩🇪
bioskin GmbH, Berlin, Germany

Phase I Study of Topical CRx-191 in Normal Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: CRx-191
Drug: mometasone furoate
Drug: nortriptyline HCl
Drug: Karison® Creme
Drug: Vehicle

First Posted Date: 2007-10-16

Last Posted Date: 2007-11-15

Lead Sponsor: Zalicus

Target Recruit Count: 20

Registration Number: NCT00544687

Locations: 🇩🇪
bioskin GmbH, Hamburg, Germany

A Comparison of Mometasone to Advair in Patients With Milder Persistent Asthma

Phase 4

Terminated

Conditions: Asthma

Interventions: Drug: Mometasone
Drug: Advair

First Posted Date: 2007-04-18

Last Posted Date: 2017-09-20

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 33

Registration Number: NCT00461812

Locations: 🇺🇸
Johns Hopkins Asthma and Allergy Center, Baltimore, Maryland, United States

Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)(COMPLETED)

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: mometasone furoate
Drug: Placebo

First Posted Date: 2007-03-28

Last Posted Date: 2022-02-09

Lead Sponsor: Organon and Co

Target Recruit Count: 426

Registration Number: NCT00453063

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

Phase 3

Completed

Conditions: Breast Cancer
Radiation Toxicity
Skin Reactions Secondary to Radiation Therapy
Dermatologic Complications

Interventions: Other: placebo
Drug: mometasone furoate

First Posted Date: 2007-02-22

Last Posted Date: 2016-08-01

Lead Sponsor: North Central Cancer Treatment Group

Target Recruit Count: 176

Registration Number: NCT00438659

Locations: 🇺🇸
Riverside Methodist Hospital Cancer Care, Columbus, Ohio, United States
🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States
🇺🇸
Mason District Hospital, Havana, Illinois, United States

and more 181 locations